Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $110,000.

  • Aclaris Therapeutics' Depreciation & Amortization (CF) fell 38.55% to $110,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $495,000, marking a year-over-year decrease of 44.51%. This contributed to the annual value of $807,000 for FY2024, which is 6.49% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Depreciation & Amortization (CF) of $110,000 as of Q3 2025, which was down 3.51% from $114,000 recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Depreciation & Amortization (CF) peaked at $288,000 during Q1 2021, and registered a low of $110,000 during Q3 2025.
  • For the 3-year period, Aclaris Therapeutics' Depreciation & Amortization (CF) averaged around $183,818, with its median value being $198,000 (2023).
  • The largest annual percentage gain for Aclaris Therapeutics' Depreciation & Amortization (CF) in the last 5 years was 143.88% (2021), contrasted with its biggest fall of 67.68% (2021).
  • Aclaris Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $197,000 in 2021, then decreased by 3.55% to $190,000 in 2022, then increased by 20.00% to $228,000 in 2023, then slumped by 37.28% to $143,000 in 2024, then plummeted by 38.55% to $110,000 in 2025.
  • Its Depreciation & Amortization (CF) was $110,000 in Q3 2025, compared to $114,000 in Q2 2025 and $128,000 in Q1 2025.